Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study - Seite 3

The PLK1 Inhibitor, Onvansertib, Synergizes with Paclitaxel in Small Cell Lung Cancer (SCLC)

• Onvansertib in combination with paclitaxel was well-tolerated and demonstrated superior efficacy over monotherapies in cisplatin sensitive and resistant SCLC PDX models.
• In cisplatin-resistant models, onvansertib plus paclitaxel led to tumor regression, with effects lasting 2 months post-treatment.
• Collectively, these preclinical findings in SCLC and previous data generated in breast cancer suggest that onvansertib in combination with paclitaxel has the potential to become a highly promising combination strategy across multiple cancer indications.
  

In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum-resistant ovarian carcinoma patient-derived xenograft models

• Onvansertib was synergistic in vitro in combination with carboplatin or gemcitabine in an ovarian cancer cell line.
• Both combinations demonstrated antitumor activity in vivo in platinum-resistant ovarian cancer PDX models and were well tolerated.
• These data support the potential of onvansertib to improve SoC treatments of platinum-resistant ovarian cancer patients.
  

All the abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR. Following the presentation, the posters will be posted to the “Scientific Presentations” section of the Cardiff Oncology website.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.